tbuckley/cabot-search huggingface dataset:
HIF-1α modulates sex-specific Th17/Treg responses during hepatic amoebiasis
Authors: Marie Groneberg, Stefan Hoenow, Claudia Marggraff, Helena Fehling, Nahla Galal Metwally, Charlotte Hansen, Iris Bruchhaus, Gisa Tiegs, Julie Sellau, Hannelore Lotter
Journal: Journal of Hepatology (2021)

An invasive form of intestinal Entamoeba (E.) histolytica infection, which causes amoebic liver abscess, is more common in men than in women. Immunopathological mechanisms are responsible for the more severe outcome in males. Here, we used a mouse model of hepatic amoebiasis to investigate the contribution of hepatic hypoxia-inducible factor (HIF)-1α to T helper 17 (Th17)/regulatory T cell (Treg) responses in the context of the sex-specific outcome of liver damage.C57BL/6J mice were infected intrahepatically with E. histolytica trophozoites. HIF-1α expression was determined by qPCR, flow cytometry and immunohistochemistry. Tregs and Th17 cells were analysed by immunohistochemistry and flow cytometry. Finally, male and female hepatocyte-specific Hif1α knockout mice were generated, and the effect of HIF-1α on abscess development, the cytokine milieu, and Th17/Treg differentiation was examined.E. histolytica infection increased hepatic HIF-1α levels, along with the elevated frequencies of hepatic Th17 and Treg cells. While the Th17 cell population was larger in male mice, Tregs characterised by increased expression of Foxp3 in female mice. Male mice displayed increased IL-6 expression, contributing to immunopathology; this increase in IL-6 expression declined upon deletion of hepatic HIF-1α. In both sexes, hepatic deletion of HIF-1α reduced the Th17 cell frequency; however, the percentage of Tregs was reduced in female mice only.Hepatic HIF-1α modulates the sex-specific outcome of murine E. histolytica infection. Our results suggest that in male mice, Th17 cells can be modulated by hepatic HIF-1α via IL-6, indicating marked involvement in the immunopathology underlying abscess development. Strong expression of Foxp3 by hepatic Tregs from female mice suggests a potent immunosuppressive function, leading to initiation of liver regeneration.Infection with the parasite Entamoeba histolytica activates immunopathological mechanisms in male mice, which lead to liver abscesses that are larger than those in female mice. In the absence of the protein HIF-1α in hepatocytes, abscess formation is reduced; moreover, the sex difference in abscess size is abolished. These results suggest that HIF-1α modulates the immune response involved in the induction of immunopathology, resulting in differential disease susceptibility in males and females.
60MO Gut microbiota and efficacy of immune-checkpoint inhibitors (ICIs) in patients (pts) with advanced solid tumor: SCRUM-Japan MONSTAR-SCREEN
Authors: K. Sawada, R. Yamashita, S. Horasawa, T. Fujisawa, A. Yoshikawa, Y. Nakamura, H. Taniguchi, S. Kadowaki, M. Hosokawa, T. Kodama, K. Kato, T. Satoh, Y. Komatsu, M. Shiota, H. Yasui, K. Yamazaki, T. Yoshino
Journal: Annals of Oncology (2021)
Targeting EYA2 tyrosine phosphatase activity in glioblastoma stem cells induces mitotic catastrophe
Authors: Guoxin Zhang, Zhen Dong, Ryan C. Gimple, Arthur Wolin, Qiulian Wu, Zhixin Qiu, Lisa M. Wood, Jia Z. Shen, Li Jiang, Linjie Zhao, Deguan Lv, Briana C. Prager, Leo J.Y. Kim, Xiuxing Wang, Lingdi Zhang, Ryan L. Anderson, Jeffrey K. Moore, Shideng Bao, Thomas H. Keller, Grace Lin, Congbao Kang, Petra Hamerlik, Rui Zhao, Heide L. Ford, Jeremy N. Rich
Journal: The Journal of Experimental Medicine (2021)

Glioblastoma ranks among the most lethal of primary brain malignancies, with glioblastoma stem cells (GSCs) at the apex of tumor cellular hierarchies. Here, to discover novel therapeutic GSC targets, we interrogated gene expression profiles from GSCs, differentiated glioblastoma cells (DGCs), and neural stem cells (NSCs), revealing EYA2 as preferentially expressed by GSCs. Targeting EYA2 impaired GSC maintenance and induced cell cycle arrest, apoptosis, and loss of self-renewal. EYA2 displayed novel localization to centrosomes in GSCs, and EYA2 tyrosine (Tyr) phosphatase activity was essential for proper mitotic spindle assembly and survival of GSCs. Inhibition of the EYA2 Tyr phosphatase activity, via genetic or pharmacological means, mimicked EYA2 loss in GSCs in vitro and extended the survival of tumor-bearing mice. Supporting the clinical relevance of these findings, EYA2 portends poor patient prognosis in glioblastoma. Collectively, our data indicate that EYA2 phosphatase function plays selective critical roles in the growth and survival of GSCs, potentially offering a high therapeutic index for EYA2 inhibitors.
1655P Real-world outcome of patients with relapsed or refractory small cell lung cancer treated with checkpoint inhibitors in Tertiary Care Centers across Germany
Authors: J.A. Stratmann, R. Timalsina, A. Atmaca, V. Rosery, N. Frost, J. Alt, C.F. Waller, N. Reinmuth, G. Rohde, M. Wermke, A. Becker von Rose, M. Moeller, M. Sebastian
Journal: Annals of Oncology (2021)
Correction: Ambient and household PM2.5 pollution and adverse perinatal outcomes: A meta-regression and analysis of attributable global burden for 204 countries and territories
Authors: Rakesh Ghosh, Kate Causey, Katrin Burkart, Sarah Wozniak, Aaron Cohen, Michael Brauer
Journal: PLoS Medicine (2021)

[This corrects the article DOI: 10.1371/journal.pmed.1003718.].
507TiP PRESERVE 1: A phase III, randomized, double-blind trial of trilaciclib versus placebo in patients receiving FOLFOXIRI/bevacizumab for metastatic colorectal cancer
Authors: J.M. Hubbard, M. Aapro, S. Shah, A.E. Gabayan, R. Siegel, Y. Pritchett, J. Yi, J. Horton, F. Ciardiello
Journal: Annals of Oncology (2021)
1298P PD-1 inhibitors combined with chemotherapy may preferentially improve survival in metastatic NSCLC with myeloid-mediated primary resistance to immunotherapy
Authors: S.C. Lau, M.J. Elliott, A. Rabinovitch, M. Makarem, S. Kuang, S. Schmid, K. Sharma, J. Lee, K.M. Mackay, S.W. Wong, B.X. Wang, P.S. Ohashi, M.S. Tsao, F.A. Shepherd, P. Bradbury, G. Liu, N. Leighl, T. McGaha, A. Sacher
Journal: Annals of Oncology (2021)
391MO Impact of diabetes and metformin use on recurrence and outcome in early colon cancer (CC) patients: A pooled analysis of 3 adjuvant trials
Authors: E.S. Bergen, N. Christou, K. Le Malicot, C. Canton, M. Di Bartolomeo, F. Galli, F. Galli, R. Labianca, Q. Shi, S.R. Alberts, R.M. Goldberg, C. Lepage, F.A. Sinicrope, J. Taieb
Journal: Annals of Oncology (2021)
Repeatability of impulse oscillometry in patients with severe asthma
Authors: Rory Chan, Rasads Misirovs, Brian Lipworth
Journal: European Respiratory Journal (2021)

Repeatability of impulse oscillometry in severe asthma is unknown. This study reports on medium term repeatability for IOS and proposes values for within subject biological variability in patients with poorly controlled severe asthma. <https://bit.ly/3a5o52W>
Improved diagnosis of antibiotic-associated haemorrhagic colitis (AAHC) in faecal specimens by a new qualitative real-time PCR assay detecting relevant toxin genes of Klebsiella oxytoca sensu lato
Authors: Eva Leitner, Michael Bozic, Sabine Kienesberger, Amar Cosic, Olfert Landt, Christoph Högenauer, Harald H. Kessler
Journal: Clinical Microbiology and Infection (2021)

Toxin-producing Klebsiella oxytoca causes antibiotic-associated haemorrhagic colitis (AAHC). The disease-relevant cytotoxins tilivalline and tilimycine produced by certain K. oxytoca isolates are encoded by the non-ribosomal peptide synthetase genes A (npsA) and B (npsB). In this study, the new LightMix® Modular kit for the detection of relevant K. oxytoca sensu lato (s.l.) toxin genes was evaluated.
1445P Zoledronic acid quarterly versus monthly conventional schedule in patients with solid tumors with bone metastases
Authors: V.T. Liutti, M.M. Piovesana, M.S. Kiara, G.V. Lucas, A.C.K. Buiar, C.C.D.S. Kasai, J.B.C. Carvalheira
Journal: Annals of Oncology (2021)
Musical features emerging from a biocultural musicality
Authors: Tudor Popescu, Nathan Oesch, Bryony Buck
Journal: Behavioral and Brain Sciences (2021)

Abstract Savage et al. make a compelling case, Mehr et al. less so, for social bonding and credible signalling, respectively, as the main adaptive function of human musicality. We express general advocacy for the former thesis, highlighting: (1) overlap between the two; (2) direct versus derived biological functions, and (3) aspects of music embedded in cultural evolution, for example, departures from tonality.
1421P EGFR inhibition in EGFR-amplified esophagogastric cancer (EGC): Retrospective global experience
Authors: S. Maron, S. Moya, F. Morano, M.J. Emmett, U. Disel, S. Chalasani, G. Ku, P.M. Kasi, N. Uboha, S. Kato, K. Shitara, Y. Nakamura, J. Chao, J. Lee, Z. Wainberg, R. Petty, F. Pietrantonio, S.J. Klempner, D.V. Catenacci
Journal: Annals of Oncology (2021)
1167P DIO2 is implicated in the antitumor effect of the lung embryonic stem cell conditioned medium and impacts prognosis in non-small cell lung cancer
Authors: J. Canals, A. Navarro, N. Viñolas, T. Díaz, R.M. Marrades, J. Moisés, M. Acosta, C. Cros, H. Bing, Y. He, D. Martinez, L. Molins, M. Monzo
Journal: Annals of Oncology (2021)
TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704)
Authors: Akihito Kawazoe, Kota Itahashi, Noboru Yamamoto, Daisuke Kotani, Yasutoshi Kuboki, Hiroya Taniguchi, Kenichi Harano, Yoichi Naito, Mitsuko Suzuki, Miki Fukutani, Tsukiko Higuchi, Takashi Ikeno, Masashi Wakabayashi, Akihiro Sato, Shohei Koyama, Hiroyoshi Nishikawa, Kohei Shitara
Journal: Clinical Cancer Research (2021)

Abstract Purpose: This is a phase Ib trial of TAS-116, an oral HSP90 inhibitor, plus nivolumab for colorectal cancer and other solid tumors. Patients and Methods: Enrolled patients received TAS-116 plus nivolumab in a dose-finding part to estimate the recommended dose. Additional patients were enrolled in a dose-expansion part. TAS-116 monotherapy (orally once daily, 80–160 mg) was administered for 2 weeks followed by the combination with nivolumab (intravenously every 2 weeks, 3 mg/kg). The primary endpoint was dose-limiting toxicities (DLT). We also conducted biomarker research using paired samples from repeated blood collections and tumor biopsies. Results: A total of 44 patients with colorectal cancer (n = 29), gastric cancer (n = 8), sarcoma (n = 5), non–small cell lung cancer (n = 1), and melanoma (n = 1) were enrolled. Eleven patients had previously received immune-checkpoint inhibitors. No DLTs were observed at all dose levels, and TAS-116 160 mg was determined as recommended dose. The common grade 3 or worse treatment-related adverse events included liver transaminase increased (7%), creatinine increased (5%), and platelet count decreased (5%). Objective tumor response was observed in 6 patients, including 4 microsatellite stable (MSS) colorectal cancers, 1 microsatellite instability-high colorectal cancer, and 1 leiomyosarcoma, resulting in an objective response rate of 16% in MSS colorectal cancer without prior immune-checkpoint inhibitors. Biomarker analysis showed that TAS-116 inhibited the activity of regulatory T cells in peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. Conclusions: TAS-116 160 mg plus nivolumab had manageable safety profiles and antitumor activity, especially for MSS colorectal cancer patients.
991P Treatment-related adverse events (TRAEs) occurring during dostarlimab therapy in the GARNET study
Authors: T. André, D. Berton, A. Oaknin, V. Moreno Garcia, G. Curigliano, J. Trigo, M-P. Barretina-Ginesta, S. Ellard, A.V. Tinker, R. Miller, J. Pikiel, V. Boni, S. Cresta, B. Pothuri, D. Roda Perez, Y. Drew, J. Veneris, E. Im, S. Banerjee
Journal: Annals of Oncology (2021)
589P Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC)
Authors: E. Perez Navarro, V. Conteduca, A. Gonzalez del Alba, B. Mellado, P. Cremaschi, O. Fernandez Calvo, M.J. Mendez Vidal, M.A. Climent Duran, I. Duran, E. Gallardo Diaz, S. Vazquez, A. Font Pous, G. Gurioli, A. Martínez, M.J. López Andreo, G. Attard, D. Castellano Gauna, E. Grande, U. Giorgi, E. Gonzalez Billalabeitia
Journal: Annals of Oncology (2021)
1524MO Patterns of care and outcomes of 64 CIC-rearranged sarcoma: A retrospective multicentre case-series within the French Sarcoma Group (FSG)
Authors: B. Mehdi, N. Gaspar, J. Gantzer, M. Toulmonde, P. Boudou Rouquette, E. Bompas, N. Firmin, T. Valentin, M. Cancel, F. Duffaud, F. Bertucci, A. Brunot, A. Dufresne, P. Marec Berard, M. Jean-Denis, I.L. Ray-Coquard, F. le Loarer, F. Tirode, J-Y. Blay, S. Watson
Journal: Annals of Oncology (2021)
Explicit motor learning interventions are still relevant for ACL injury rehabilitation: do not put all your eggs in the implicit basket!: Letter to the Editor
Authors: Anne Benjaminse, Alli Gokeler
Journal: British Journal of Sports Medicine (2021)

We read the recent manuscript by Kal et al.1 ‘Explicit motor learning interventions are still relevant for ACL injury rehabilitation: do not put all your eggs in the implicit basket‘ with great interest. The authors did a commendable job summarizing the current literature and we highly respect them for being critical, to foster academic discussions to move science forward. We do however have some concerns regarding the methodology and interpretations made by the authors.
Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia
Authors: Andreas Greinacher, Kathleen Selleng, Raghavendra Palankar, Jan Wesche, Stefan Handtke, Martina Wolff, Konstanze Aurich, Michael Lalk, Karen Methling, Uwe Völker, Christian Hentschker, Stephan Michalik, Leif Steil, Alexander Reder, Linda Schönborn, Martin Beer, Kati Franzke, Andreas Büttner, Boris Fehse, Evi X. Stavrou, Chandini Rangaswamy, Reiner K. Mailer, Hanna Englert, Maike Frye, Thomas Thiele, Stefan Kochanek, Lea Krutzke, Florian Siegerist, Nicole Endlich, Theodore E. Warkentin, Thomas Renné
Journal: Blood (2021)
1845P Features of clinical trials leading to oncologic drugs approval in europe
Authors: S. Duranti, P. Lombardi, R. Falcone, M. Filetti, A. Pietragalla, F. Paroni Sterbini, D. Lorusso, A. Fabi, C. Nero, F. Ciccarone, G. Scambia, G. Daniele
Journal: Annals of Oncology (2021)
1202P ALK-2016-CPHG: French cohort of advanced non-small cell lung cancer (aNSCLC) with ALK (ALK+) or ROS1 (ROS1+) gene rearrangement treated by crizotinib
Authors: D. Debieuvre, C. Locher, H. Morel, A. Baranzelli, L. Falchero, P. Romand, M. Roa, B. Delclaux, A. Bizieux-Thaminy, A-S. Bugnet, J. Grelier, C. Dayen, C. Decroisette, S. Martinez, F. Goutorbe, L. Moreau, N. Cloarec, O. Molinier, J. Le Treut, Y. Duval
Journal: Annals of Oncology (2021)
216P Prognostic role of Ki67 cutoff and mPEPI score for neoadjuvant ‘chemotherapy’ in locally advanced HER2-negative ‘luminal’ breast cancer
Authors: M. Dogan, C. Karacin, O. Kaman, M.Z. Bulut, G. Kiziltan, L. Dogan, B.O. Cakmak Oksuzoglu
Journal: Annals of Oncology (2021)
Association of Labor Epidural Analgesia With Autism Spectrum Disorder in Children
Authors: Anders Pretzmann Mikkelsen, Iben Katinka Greiber, Nikolai Madrid Scheller, Øjvind Lidegaard
Journal: JAMA (2021)

<h3>Importance</h3> A recent cohort study found that epidural analgesia during labor was associated with an increased risk of autism in offspring. <h3>Objective</h3> To investigate if labor epidural increases the risk of autism in offspring. <h3>Design, Setting, and Participants</h3> This nationwide retrospective cohort study identified all live-born children in Denmark between January 2006 and December 2013. Follow-up commenced at children's first birthday and ended in December 2017. Among 485 093 live-born children, 5915 were excluded because of occurrences during the first year of life including death, emigration, misregistration of birth, diagnosis of disease inherently linked to autism, or diagnosis of autism. <h3>Exposures</h3> Administration of epidural analgesia during labor, as identified by procedure code. <h3>Main Outcomes and Measures</h3> The main outcome of interest was incident diagnosis of autism spectrum disorder based on<i>International Statistical Classification of Diseases and Related Health Problems, 10th Revision</i>codes in the Danish Psychiatric Central Register or National Patient Register. Hazard ratios were estimated using Cox regression, adjusted for covariates describing maternal comorbidity, sociodemographic factors, lifestyle, pregnancy, psychiatric illness, psychotropic medication, medical-seeking behavior, and family history of autism. A secondary analysis used a within-mother design including only children of mothers with both exposure and nonexposure to labor epidural analgesia in different deliveries. <h3>Results</h3> The cohort included 479 178 children (233 405 girls [48.7%]; median maternal age at delivery, 30.9 [IQR, 27.6-34.2] years); of these, 92 900 (19.4%) were exposed to epidural analgesia during labor. Median follow-up was 7.0 years (IQR, 4.9-9.0 years), and by the end of follow-up, 6428 children (1.3%) had been diagnosed with autism. Exposed children had an autism diagnosis incidence rate of 23.1 per 10 000 person-years compared with 18.5 per 10 000 person-years in the unexposed group (crude hazard ratio, 1.29 [95% CI, 1.21-1.37]; adjusted hazard ratio, 1.05 [95% CI, 0.98-1.11]). A secondary within-mother analysis including 59 154 children (12.3%) estimated an autism diagnosis incidence rate of 20.8 per 10 000 person-years in the exposed group and 17.1 per 10 000 person-years in the unexposed group (adjusted hazard ratio, 1.05 [95% CI, 0.90-1.21]). <h3>Conclusions and Relevance</h3> In this nationwide cohort study of Danish children, maternal exposure to epidural analgesia during labor was not significantly associated with autism spectrum disorder in offspring.
LBA28 STAR: A randomised multi-stage phase II/III trial of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal Cancer (RCC)
Authors: J.E. Brown, K-L. Royle, C. Ralph, D. Meads, A. Martin, H. Howard, C. Linsley, J. Swain, T.B. Powles, R. Jones, T. Eisen, A. Maraveyas, R. Griffiths, O. Din, V. Goh, T. Wah, P. Selby, J. Hewison, J. Brown, F. Collinson
Journal: Annals of Oncology (2021)
609P Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2006 to 2019
Authors: S.J. Freedland, R. Sandin, S.T. Tagawa, Z. Klaassen, R.L. Bitting, K. Ramaswamy, B. Emir, C. Bland, A. Hong, H. Yang, W. Gao, W. Song, D.J. George
Journal: Annals of Oncology (2021)
758P Concordance between multiple HRD assays is substantial in high-grade ovarian cancer
Authors: W. Weichert, S. Bartels, G. Baretton, E.I. Braicu, M.C. Demes, V. Endris, S. Herold, L. Heukamp, M. Hummel, U. Lehmann, S. Merkelbach-Bruse, N. Pfarr, R. Rad, J. Sehouli, J. Siemanowski, A. Stenzinger, K. von Schwarzenberg, C. Vollbrecht, P. Wild, D. Zocholl
Journal: Annals of Oncology (2021)
326P National multicentre retrospective study on metastatic breast cancer patients to characterize long responder under eribulin: LORELINE study
Authors: M.A. Mouret Reynier, M-J. Paillard, L. Uwer, I. Molnar, F. Kwiatkowski, S. Lusho, N. Dohollou, T. Petit, N. Hajjaji, L. Boudin, V. Lorgis, J-P.P. Jacquin, C. Abrial, J. Passildas Jahanmohan
Journal: Annals of Oncology (2021)
ORMDL3 regulates cigarette smoke–induced endoplasmic reticulum stress in airway smooth muscle cells
Authors: Rui Chen, Charalambos Michaeloudes, Yingmin Liang, Pankaj K. Bhavsar, Kian Fan Chung, Mary S.M. Ip, Judith C.W. Mak
Journal: Journal of Allergy and Clinical Immunology (2021)
725MO Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer
Authors: S. Banerjee, R. Grochot, R. Shinde, J. Lima, M. Krebs, R. Rahman, M. Little, N. Tunariu, A. Curcean, H. Badham, M. Mahmud, A. Turner, M. Parmar, C. Yap, A. Minchom, J. Lopez, J. de Bono, U. Banerji
Journal: Annals of Oncology (2021)
Myeloproliferative Neoplasms and Depressive Symptoms, Diagnosis, and Associations
Authors: Leslie Padrnos, Robyn M. Scherber, Blake T. Langlais, Amylou Dueck, Jennifer Huberty, Holly L. Geyer, Krisstina L. Gowin, Heidi Kosiorek, Marlene Bruso, Zhenya Senyak, Matthew M Clark, Michael Boxer, Mary Cotter, Claire N. Harrison, Ruben A Mesa
Journal: Blood (2017)
Balloon-Occluded Transarterial Chemoembolization: In Which Size Range Does It Perform Best? A Comparison of Its Efficacy versus Conventional Transarterial Chemoembolization, Using Propensity Score Matching
Authors: Rita Golfieri, Mario Bezzi, Gontran Verset, Fabio Fucilli, Cristina Mosconi, Alberta Cappelli, Alexandro Paccapelo, Pierleone Lucatelli, Nicolas Magand, Agnes Rode, Thierry De Baere
Journal: Liver Cancer (2021)

&lt;b&gt;&lt;i&gt;Introduction:&lt;/i&gt;&lt;/b&gt; The aim of this multicenter comparison of balloon-occluded transarterial chemoembolization (B-TACE) versus conventional TACE (cTACE) in treating hepatocellular carcinoma (HCC) was to assess in which size range the 2 techniques offered higher complete response (CR) and objective response (OR) rates in a single session, and to evaluate the possibility of using B-TACE to reduce the need for re-treatment. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; 325 patients were retrospectively evaluated: 91 patients in the B-TACE group (22 with cTACE [B-cTACE] and 69 with drug-eluting microsphere TACE [B-DEM-TACE]) and 234 in the cTACE group. The results were compared according to tumor size: (A) &amp;#x3c;30 mm, (B) 30–50 mm, and (C) &amp;#x3e;50 mm; OR and CR rates after the first session and the number of TACE re-interventions within a 6-month period were also evaluated using propensity score matching (PSM). &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; The best target ORs were very high (93.2%) and similar between the 2 treatments both before (94.4% for cTACE and 90.1% for B-TACE) and after PSM (94.5% for cTACE and 90.1%; &lt;i&gt;p&lt;/i&gt; = 0.405), with slightly better results for the cTACE cohort probably due to better cTACE effectiveness in smaller lesions. In lesions &amp;#x3c;30 mm, cTACE obtained a slightly higher CR rate than B-TACE (61.9 vs. 56.3%, &lt;i&gt;p&lt;/i&gt; = 0.680), whereas in intermediate-sized HCCs (30–50 mm), B-TACE showed a significant superiority in achieving a CR (72.3 vs. 54.1%, respectively; &lt;i&gt;p&lt;/i&gt; = 0.047). In larger lesions (&amp;#x3e;50 mm), cTACE and B-TACE performed equally, with a poor CR rate (22.6 vs. 23.1%, respectively; &lt;i&gt;p&lt;/i&gt; = 1.000). These results were additionally confirmed using PSM. The patients treated with B-TACE had a significantly lower re-treatment rate than the cTACE cohort (12.1 vs. 26.9%, respectively; &lt;i&gt;p&lt;/i&gt; = 0.005). B-cTACE and B-DEM-TACE demonstrated similar ORs, with a slightly better CR rate for B-cTACE (68.2 vs. 56.5%, respectively; &lt;i&gt;p&lt;/i&gt; = 0.456). &lt;b&gt;&lt;i&gt;Conclusion:&lt;/i&gt;&lt;/b&gt; In HCCs of 30–50 mm, B-TACE should be preferred to cTACE, whereas in smaller nodules (&amp;#x3c;30 mm), cTACE can suffice in achieving a good CR rate. The statistically significant lower re-treatment rate of the B-TACE cohort after a single procedure reduced the risk of complications due to multiple TACE, which could worsen the patient prognosis.
1018P Characterization of liver function tests following tebentafusp in phase III randomized trial comparing tebentafusp with investigator’s choice in first line metastatic uveal melanoma (mUM)
Authors: B. Chmielowski, E. Kapiteijn, P.A. Ascierto, F. Meier, S.E. Abdullah, S. Lockwood, P. Mendez, I. Puzanov
Journal: Annals of Oncology (2021)